Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anthrax toxin antagonist - Altimmune

Drug Profile

Anthrax toxin antagonist - Altimmune

Alternative Names: DNI Therapeutic - Altimmune; Dominant negative inhibitor - Altimmune; Therapeutic anthrax antitoxin - Altimmune; ToxBlox

Latest Information Update: 05 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmAthene
  • Class
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 04 May 2017 Altimmune merged with PharmAthene and the combined entity was renamed as Altimmune
  • 15 Feb 2017 PharmAthene has patent protection for anthrax vaccine formulation and uses thereof in Europe (PharmAthene 10-K, March 2017)
  • 31 Jan 2017 PharmAthene has patent protection for anthrax vaccine formulation and uses thereof in Canada (PharmAthene 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top